PODD
INSULET CORP
NASDAQ · Healthcare · Medical - Devices · US
$141.96
+0.61%Year over year
Reported trailing growth
- Revenue
- +29.4%
- EBITDA
- +61.4%
- EBIT
- +26.6%
- EPS
- +59.1%
- Free cash flow
- -23.2%
- Operating cash flow
- +0.9%
Forward estimates
Based on analyst estimates
- Revenue
- +18.7%
- EBITDA
- +27.6%
- EPS
- +36.6%
Three-year CAGR
- Revenue
- +27.5%
- EBITDA
- +67.2%
- EBIT
- +132.7%
- Net income
- +277.3%
- EPS
- +275.5%
- Free cash flow
- +132.1%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026